Revolution Medicines Inc (NASDAQ: RVMD) |
|
*Market share is calculated based on total revenue.
News about Revolution Medicines Inc Contracts |
April 8, 2024
Revolution Medicines Announces Groundbreaking Discovery and Preclinical Profile of New Class of RAS(ON) Multi-Selective Inhibitors with Unprecedented Anti-Tumor Activity in RAS-Mutant Pancreatic Cancer ModelsRevolution Medicines, a leading biotechnology company focused on developing innovative cancer treatments, has recently made significant progress in the field of oncology. In a press release issued today, the company announced the publication of two original papers in the prestigious scientific journal Nature, showcasing the discovery and translational implications of their latest breakthrough compound, RMC-7977.RMC-7977 is a RAS(ON) multi-selective tri-complex inhibitor, specifically designed to block th...
|
Publicly Traded Peers of Revolution Medicines Inc
Aceragen Inc Share Performance
0.00%
One Year
|
Aceragen Inc
Profile
Aceragen Inc is a biotechnology company that follows a business model focused on the research, development, and commercialization of innovative gene-based therapies for treating genetic diseases. They aim to leverage their expertise in genetic medicine to create and deliver advanced therapies that address unmet medical needs and improve patient outcomes.
More about Aceragen Inc 's Market Share
|
Arcellx Inc Share Performance
+12.28%
30 Days
|
Arcellx Inc
Profile
Arcellx Inc operates on a business model focused on developing and commercializing next-generation cell therapies for the treatment of various diseases by utilizing its proprietary ARC-SparX platform technology. The company intends to leverage its technology to create novel and improved therapies, targeting both liquid and solid tumors, aiming for better patient outcomes.
More about Arcellx Inc 's Market Share
|
Alector Inc Share Performance
+6.94%
Over The Past 5 Days
|
Alector Inc
Profile
Alector Inc's business model focuses on developing novel therapeutics for neurodegenerative diseases using its proprietary platform and partnering with pharmaceutical companies for clinical trials and commercialization.
More about Alector Inc 's Market Share
|
Aligos Therapeutics Inc Share Performance
+32.02%
30 Days
|
Aligos Therapeutics Inc
Profile
Aligos Therapeutics Inc's business model involves developing innovative therapeutics for the treatment of viral diseases.
More about Aligos Therapeutics Inc 's Market Share
|
Allogene Therapeutics Inc Share Performance
+20.72%
30 Days
|
Allogene Therapeutics Inc
Profile
Allogene Therapeutics Inc has a business model that focuses on developing and commercializing innovative allogeneic CAR T cell therapies for the treatment of cancer.
More about Allogene Therapeutics Inc 's Market Share
|
Ambrx Biopharma Inc Share Performance
+0.21%
Over The Past 5 Days
|
Ambrx Biopharma Inc
Profile
Ambrx Biopharma Inc's business model can be described as a biopharmaceutical company that focuses on developing protein therapeutics through the use of its proprietary technology called ReCODE?.
More about Ambrx Biopharma Inc 's Market Share
|
Amgen Inc Share Performance
+5.47%
30 Days
|
Amgen Inc
Profile
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
More about Amgen Inc 's Market Share
|
Apogee Therapeutics Inc Share Performance
+10.84%
Over The Past 5 Days
|
Apogee Therapeutics Inc
Profile
Apogee Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative therapies for various medical conditions. Their business model revolves around conducting extensive research to identify potential drug candidates, and then advancing them through preclinical and clinical trials to secure regulatory approvals. By licensing or partnering with larger pharmaceutical companies, Apogee Therapeutics aims to bring these drugs to market and improve patient outcomes.
More about Apogee Therapeutics Inc 's Market Share
|
Aptose Biosciences Inc Share Performance
-51.00%
Over The Past 5 Days
|
Aptose Biosciences Inc
Profile
Aptose Biosciences Inc has a business model focused on developing and commercializing targeted therapies for the treatment of various types of cancers. This involves conducting research, preclinical and clinical development activities, and eventually partnering or licensing their drug candidates to pharmaceutical companies for further development and commercialization.
More about Aptose Biosciences Inc 's Market Share
|
Armata Pharmaceuticals Inc Share Performance
-4.59%
Over The Past 5 Days
|
Armata Pharmaceuticals Inc
Profile
Armata Pharmaceuticals Inc operates on a research and development business model focused on discovering and developing bacteriophage-based therapies to combat antibiotic-resistant infections. They utilize their proprietary phage technology platform to create novel pharmaceutical products targeting various bacterial diseases.
More about Armata Pharmaceuticals Inc 's Market Share
|
Atara Biotherapeutics Inc Share Performance
-37.71%
This Year
|
Atara Biotherapeutics Inc
Profile
Atara Biotherapeutics Inc is a biotechnology company that focuses on developing therapies for patients with serious medical conditions. They utilize a personalized medicine approach to create off-the-shelf, allogeneic T-cell immunotherapies. By leveraging their expertise in T-cell immunotherapy and genetic engineering, they aim to provide innovative treatments with the potential for broad patient reach.
More about Atara Biotherapeutics Inc 's Market Share
|
Autolus Therapeutics Plc Share Performance
-9.79%
Over The Past 5 Days
|
Autolus Therapeutics Plc
Profile
Autolus Therapeutics Plc is a biopharmaceutical company that focuses on the development and commercialization of next-generation engineered T-cell therapies for the treatment of cancer. Their business model is centered around utilizing innovative technology and expertise to create and advance novel therapies aimed at improving patient outcomes in oncology.
More about Autolus Therapeutics Plc's Market Share
|
Biocryst Pharmaceuticals Inc Share Performance
-6.66%
Over The Past 5 Days
|
Biocryst Pharmaceuticals Inc
Profile
Biocryst Pharmaceuticals Inc is a biotechnology company that focuses on the discovery and development of small-molecule drugs for rare diseases. They leverage their expertise in protein crystallography and drug design to create innovative therapies targeting specific proteins associated with certain diseases. Biocryst aims to bring these treatments to market by partnering with pharmaceutical companies or pursuing commercialization independently.
More about Biocryst Pharmaceuticals Inc 's Market Share
|
Biogen Inc Share Performance
-4.89%
Over The Past 5 Days
|
Biogen Inc
Profile
Biogen Incs business model focuses on researching, developing, and commercializing innovative therapies primarily for neurological and neurodegenerative diseases, emphasizing advancements in precision medicine and patient care.
More about Biogen Inc 's Market Share
|
Cullinan Therapeutics Inc Share Performance
-4.65%
This Quarter
|
Cullinan Therapeutics Inc
Profile
Cullinan Oncology Inc's business model focuses on developing innovative cancer treatments by identifying and acquiring promising drug candidates through collaborations and partnerships with academic institutions and biotechnology companies. They prioritize the advancement of these therapies towards clinical trials and commercialization, aiming to address unmet medical needs in the field of oncology.
More about Cullinan Therapeutics Inc 's Market Share
|
Coherus Biosciences inc Share Performance
-54.93%
One Year
|
Coherus Biosciences inc
Profile
Coherus Biosciences Inc is a biopharmaceutical company focused on developing and commercializing high-quality biosimilar therapeutics. Their business model revolves around leveraging their expertise in cell culture, protein purification, formulation development, and analytical methods to manufacture and market biosimilar products. By providing cost-effective alternatives to expensive biologic drugs, Coherus Biosciences aims to make healthcare more accessible and affordable for patients.
More about Coherus Biosciences inc 's Market Share
|
Calidi Biotherapeutics Inc Share Performance
-15.85%
30 Days
|
Calidi Biotherapeutics Inc
Profile
Calidi Biotherapeutics Inc's business model revolves around developing and commercializing innovative cell-based immunotherapies for the treatment of cancer.
More about Calidi Biotherapeutics Inc 's Market Share
|
Compass Therapeutics Inc Share Performance
+14.76%
30 Days
|
Compass Therapeutics Inc
Profile
Compass Therapeutics Inc operates as a biotechnology company focused on discovering and developing novel antibody therapeutics for the treatment of cancer and autoimmune diseases. Their business model revolves around leveraging their proprietary Targeted Immunomodulation platform to identify and advance multiple antibody candidates through preclinical and clinical development stages.
More about Compass Therapeutics Inc 's Market Share
|
Cardiol Therapeutics inc Share Performance
+6.57%
This Year
|
Cardiol Therapeutics inc
Profile
Cardiol Therapeutics Inc. operates on a business model focused on the research and development of pharmaceutical-grade cannabidiol (CBD) and targeted therapies for cardiovascular diseases. The company aims to leverage its expertise to develop innovative and effective treatments to address unmet medical needs in the field of heart-related conditions.
More about Cardiol Therapeutics inc 's Market Share
|
Cel sci Corporation Share Performance
-81.71%
This Year
|
Cel sci Corporation
Profile
Cel-Sci Corporation's business model revolves around developing and commercializing immunotherapy drugs for the treatment of infectious diseases and certain types of cancer.
More about Cel sci Corporation's Market Share
|
Dyadic International Inc Share Performance
-45.98%
This Year
|
Dyadic International Inc
Profile
Dyadic International Inc's business model revolves around developing and licensing proprietary microbial strains and technologies for use in the biopharmaceutical, biofuels, and industrial enzyme industries.
More about Dyadic International Inc's Market Share
|
Enzon Pharmaceuticals inc Share Performance
0.00%
Over The Past 5 Days
|
Enzon Pharmaceuticals inc
Profile
Enzon Pharmaceuticals Inc. operates under a business model that focuses on the research, development, and commercialization of therapeutic drugs to address unmet medical needs. The company primarily employs a licensing strategy, partnering with other pharmaceutical companies to advance their drug candidates through clinical development and regulatory approval. By leveraging collaborations and out-licensing opportunities, Enzon aims to bring new therapies to market efficiently while maximizing shareholder value.
More about Enzon Pharmaceuticals inc 's Market Share
|
Tradeup Acquisition Corp Share Performance
-2.89%
Over The Past 5 Days
|
Tradeup Acquisition Corp
Profile
Estrella Immunopharma Inc is a biotechnology company that focuses on developing innovative immunotherapies. They have a business model centered around researching, developing, and commercializing novel treatments for various diseases. Their approach includes leveraging the power of the immune system to target and eradicate diseases, with a particular emphasis on cancer.
More about Tradeup Acquisition Corp's Market Share
|
Exelixis Inc Share Performance
+91.31%
One Year
|
Exelixis Inc
Profile
Exelixis Inc's business model is focused on the discovery, development, and commercialization of innovative therapies for the treatment of cancer.
More about Exelixis Inc 's Market Share
|
Fate Therapeutics Inc Share Performance
-16.12%
Over The Past 5 Days
|
Fate Therapeutics Inc
Profile
Fate Therapeutics Inc's business model revolves around the development and commercialization of innovative cell-based therapies to treat various diseases.
More about Fate Therapeutics Inc 's Market Share
|
Fusion Pharmaceuticals Inc Share Performance
+72.40%
This Quarter
|
Fusion Pharmaceuticals Inc
Profile
Fusion Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development and commercialization of targeted alpha therapeutics for the treatment of cancer. Their business model revolves around harnessing the power of radiation to selectively kill cancer cells while sparing healthy tissues. By combining targeted alpha therapy with various cancer-targeting agents, they aim to develop innovative treatments that offer improved efficacy and reduced side effects for patients.
More about Fusion Pharmaceuticals Inc 's Market Share
|
Gilead Sciences Inc Share Performance
-1.19%
Over The Past 5 Days
|
Gilead Sciences Inc
Profile
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
More about Gilead Sciences Inc 's Market Share
|
Gamida Cell Ltd Share Performance
-88.89%
30 Days
|
Gamida Cell Ltd
Profile
Gamida Cell Ltd's business model is focused on developing and bringing innovative cell therapies to market for the treatment of various diseases, with a particular emphasis on hematological malignancies and serious blood disorders.
More about Gamida Cell Ltd 's Market Share
|
Genenta Science S p a Share Performance
+1.17%
This Quarter
|
Genenta Science S p a
Profile
Genenta Science S.p.A. operates on a business model focused on the development of immuno-gene therapies for the treatment of cancer. They aim to leverage their proprietary technology to genetically modify autologous hematopoietic stem cells and engineer them to express immunomodulatory protein IL-12. These modified cells are then reinfused into patients to stimulate an immune response against tumors, potentially offering a novel and personalized approach to cancer treatment.
More about Genenta Science S p a 's Market Share
|
Halozyme Therapeutics Inc Share Performance
+12.43%
This Year
|
Halozyme Therapeutics Inc
Profile
Halozyme Therapeutics Inc is a biotechnology company that primarily focuses on developing and commercializing novel oncology therapies. Their business model involves leveraging their proprietary enzyme technology to improve the delivery and effectiveness of therapeutic drugs. By partnering with pharmaceutical companies, Halozyme aims to license their technology and collaborate on the development and commercialization of innovative therapies for various diseases.
More about Halozyme Therapeutics Inc 's Market Share
|
Immunitybio inc Share Performance
+8.10%
30 Days
|
Immunitybio inc
Profile
Immunitybio Inc operates on a business model that focuses on developing and commercializing innovative immunotherapies and vaccines to address various diseases and medical conditions. They aim to use their broad scientific expertise, technology platforms, and strategic partnerships to advance their products and improve patient outcomes in healthcare.
More about Immunitybio inc 's Market Share
|
In8bio Inc Share Performance
-93.09%
One Year
|
In8bio Inc
Profile
In8bio Inc operates as a clinical-stage biotechnology company that focuses on developing transformative therapies for the treatment of cancer and other diseases. The company follows a research and development model centered on leveraging their proprietary platform to identify and optimize novel genetic circuits for targeted cell-based therapies.
More about In8bio Inc 's Market Share
|
Iovance Biotherapeutics inc Share Performance
-40.11%
This Quarter
|
Iovance Biotherapeutics inc
Profile
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
More about Iovance Biotherapeutics inc 's Market Share
|
Innate Pharma Sa Share Performance
+1.34%
This Year
|
Innate Pharma Sa
Profile
Innate Pharma SA's business model revolves around the development and commercialization of innovative cancer immunotherapies.
More about Innate Pharma Sa's Market Share
|
Iteos Therapeutics Inc Share Performance
-37.34%
One Year
|
Iteos Therapeutics Inc
Profile
Iteos Therapeutics Inc is a company that focuses on developing innovative immunotherapies to treat cancer by targeting the tumor microenvironment.
More about Iteos Therapeutics Inc 's Market Share
|
Jasper Therapeutics Inc Share Performance
+13.18%
30 Days
|
Jasper Therapeutics Inc
Profile
Jasper Therapeutics Inc operates in the biotechnology industry, focusing on developing stem cell-based therapies for hematopoietic and immune system disorders. Their business model involves utilizing innovative stem cell technologies and partnerships within the medical community to advance their research and bring potential treatments to patients in need.
More about Jasper Therapeutics Inc's Market Share
|
Ladrx Corporation Share Performance
0.00%
30 Days
|
Ladrx Corporation
Profile
Ladrx Corporation operates as a global technology solutions provider, offering a range of products and services in various industries. Their business model revolves around leveraging innovative technologies to develop tailored solutions for their clients, with a focus on enhancing operational efficiency and driving digital transformation. By combining their expertise in multiple domains and maintaining strong partnerships, Ladrx aims to deliver value-driven solutions to meet the evolving needs of businesses worldwide.
More about Ladrx Corporation's Market Share
|
Lexeo Therapeutics Inc Share Performance
-10.05%
Over The Past 5 Days
|
Lexeo Therapeutics Inc
Profile
Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.
More about Lexeo Therapeutics Inc 's Market Share
|
Mesoblast Ltd Share Performance
-10.69%
This Quarter
|
Mesoblast Ltd
Profile
Mesoblast Ltd is a biotechnology company that operates on a business model focused on the development and commercialization of proprietary cell-based regenerative medicines. They aim to transform the treatment of various degenerative diseases by utilizing their patented technology and strategic partnerships with pharmaceutical companies.
More about Mesoblast Ltd's Market Share
|
Molecular Partners Ag Share Performance
-43.28%
One Year
|
Molecular Partners Ag
Profile
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
More about Molecular Partners Ag's Market Share
|
Orchard Therapeutics Plc Share Performance
+4.44%
This Quarter
|
Orchard Therapeutics Plc
Profile
Orchard Therapeutics Plc operates as a biotechnology company specializing in gene therapies for rare diseases. Their business model involves developing and commercializing potentially curative gene therapies to address the underlying cause of these diseases. They collaborate with academic and industry partners to advance their research and utilize their expertise to bring innovative therapies to patients in need.
More about Orchard Therapeutics Plc's Market Share
|
Peak Bio Inc Share Performance
0.00%
This Quarter
|
Peak Bio Inc
Profile
Peak Bio Inc is a biotechnology company specializing in the development and commercialization of innovative medical products. Their business model focuses on conducting extensive research and development to create cutting-edge biopharmaceuticals. These products are then marketed and distributed to healthcare providers and patients, aiming to improve patient outcomes and contribute to advancements in the healthcare industry.
More about Peak Bio Inc 's Market Share
|
Mosaic Immunoengineering Inc Share Performance
0.00%
One Year
|
Mosaic Immunoengineering Inc
Profile
Mosaic Immunoengineering Inc's business model revolves around leveraging cutting-edge technologies and expertise in immunoengineering to develop innovative solutions and therapies for immune-related diseases.
More about Mosaic Immunoengineering Inc 's Market Share
|
Sab Biotherapeutics Inc Share Performance
-9.09%
Over The Past 5 Days
|
Sab Biotherapeutics Inc
Profile
Sab Biotherapeutics Inc's business model focuses on developing and producing innovative antibody therapeutics using advanced genetic engineering techniques.
More about Sab Biotherapeutics Inc 's Market Share
|
Seagen Inc Share Performance
+4.77%
Over The Past 5 Days
|
Seagen Inc
Profile
Seagen Inc is a biotechnology company that focuses on developing and commercializing innovative cancer therapeutics. Their business model revolves around research and development of targeted antibody-based drugs, specifically using their proprietary antibody-drug conjugate (ADC) technology. Seagen Inc also seeks strategic collaborations and partnerships with other pharmaceutical companies to enhance their product pipeline and expand their market reach.
More about Seagen Inc 's Market Share
|
Sorrento Therapeutics Inc Share Performance
+230.00%
Over The Past 5 Days
|
Sorrento Therapeutics Inc
Profile
Sorrento Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for various diseases, including cancer, autoimmune disorders, and pain management.
More about Sorrento Therapeutics Inc 's Market Share
|
Sutro Biopharma Inc Share Performance
-6.45%
30 Days
|
Sutro Biopharma Inc
Profile
Sutro Biopharma Inc has a business model focused on developing and commercializing innovative antibody-based therapeutics.
More about Sutro Biopharma Inc 's Market Share
|
Springworks Therapeutics Inc Share Performance
+29.48%
One Year
|
Springworks Therapeutics Inc
Profile
Springworks Therapeutics Inc is a biopharmaceutical company with a focus on developing innovative medicines for underserved patient populations. Their business model revolves around identifying promising therapeutic candidates, which could address significant unmet needs, and advancing them through various stages of clinical development. They collaborate with academic institutions, research organizations, and industry partners to accelerate the discovery and development of potential treatments, ultimately aiming to bring these therapies to market and improve patient outcomes.
More about Springworks Therapeutics Inc 's Market Share
|
Tscan Therapeutics Inc Share Performance
-81.55%
One Year
|
Tscan Therapeutics Inc
Profile
Tscan Therapeutics Inc is a biotechnology company that focuses on developing and commercializing T cell receptor therapies for cancer patients. Their business model revolves around leveraging their T cell platform to develop innovative treatments and secure partnerships with other pharmaceutical companies for clinical development and commercialization.
More about Tscan Therapeutics Inc 's Market Share
|
Turnstone Biologics Corp Share Performance
-38.06%
This Year
|
Turnstone Biologics Corp
Profile
Turnstone Biologics Corp is a biotechnology company that focuses on developing innovative cancer treatments. Their business model includes leveraging their proprietary vaccinia virus-based platform to engineer oncolytic viral immunotherapies. These therapies are designed to selectively target and destroy cancer cells while also activating the patient's immune system to generate a lasting anti-tumor response.
More about Turnstone Biologics Corp 's Market Share
|
Vir Biotechnology Inc Share Performance
+13.48%
30 Days
|
Vir Biotechnology Inc
Profile
Vir Biotechnology Inc is a clinical-stage immunology company that focuses on developing and commercializing innovative treatments for infectious diseases. Their business model revolves around the discovery and development of antibody therapies and other immunological approaches to combat a wide range of viral pathogens. They collaborate with leading research institutions and pharmaceutical companies to accelerate the development and commercialization of their products.
More about Vir Biotechnology Inc 's Market Share
|
Zura Bio Limited Share Performance
-15.85%
This Quarter
|
Zura Bio Limited
Profile
Zura Bio Limited operates on a business model focused on developing and commercializing innovative bio-based solutions.
More about Zura Bio Limited's Market Share
|
Astrazeneca Plc Share Performance
+8.15%
30 Days
|
Astrazeneca Plc
Profile
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
More about Astrazeneca Plc's Market Share
|
Black Diamond Therapeutics Inc Share Performance
+35.09%
This Quarter
|
Black Diamond Therapeutics Inc
Profile
Black Diamond Therapeutics Inc's business model is centered around developing targeted therapies for cancer patients by leveraging its proprietary platform and expertise in precision medicine.
More about Black Diamond Therapeutics Inc 's Market Share
|
Bristol myers Squibb Company Share Performance
-16.85%
This Year
|
Bristol myers Squibb Company
Profile
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
More about Bristol myers Squibb Company's Market Share
|
Merck and Co Inc Share Performance
-2.54%
Over The Past 5 Days
|
Merck and Co Inc
Profile
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
More about Merck and Co Inc 's Market Share
|
Mural Oncology Plc Share Performance
-5.75%
Over The Past 5 Days
|
Mural Oncology Plc
Profile
Mural Oncology Plc's business model focuses on developing and commercializing innovative cancer therapies. They likely collaborate with research institutes and pharmaceutical companies to acquire promising drug candidates and conduct rigorous clinical trials. Their revenue is generated through licensing, partnerships, and potential product sales, helping provide solutions for patients suffering from various forms of cancer.
More about Mural Oncology Plc's Market Share
|
Novartis Ag Share Performance
+12.99%
One Year
|
Novartis Ag
Profile
Novartis AG's business model is centered around the development, manufacturing, and marketing of innovative pharmaceutical products.
More about Novartis Ag's Market Share
|
Pfizer Inc Share Performance
-8.45%
This Quarter
|
Pfizer Inc
Profile
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
More about Pfizer Inc's Market Share
|
Sources: Revolution Medicines Inc and all companies mentioned above in this report
|